A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

Kenya Medical Research Institute, Centre for Geographical Medicine Research (Coast), Kilifi, Kenya.
PLoS Clinical Trials (Impact Factor: 4.77). 02/2006; 1(6):e29. DOI: 10.1371/journal.pctr.0010029
Source: PubMed

ABSTRACT The objective was to measure the efficacy of the vaccination regimen FFM ME-TRAP in preventing episodes of clinical malaria among children in a malaria endemic area. FFM ME-TRAP is sequential immunisation with two attenuated poxvirus vectors (FP9 and modified vaccinia virus Ankara), which both deliver the pre-erythrocytic malaria antigen construct multiple epitope-thrombospondin-related adhesion protein (ME-TRAP).
The trial was randomised and double-blinded.
The setting was a rural, malaria-endemic area of coastal Kenya.
We vaccinated 405 healthy 1- to 6-year-old children.
Participants were randomised to vaccination with either FFM ME-TRAP or control (rabies vaccine).
Following antimalarial drug treatment children were seen weekly and whenever they were unwell during nine months of monitoring. The axillary temperature was measured, and blood films taken when febrile. The primary analysis was time to a parasitaemia of over 2,500 parasites/mul.
The regime was moderately immunogenic, but the magnitude of T cell responses was lower than in previous studies. In intention to treat (ITT) analysis, time to first episode was shorter in the FFM ME-TRAP group. The cumulative incidence of febrile malaria was 52/190 (27%) for FFM ME-TRAP and 40/197 (20%) among controls (hazard ratio = 1.52). This was not statistically significant (95% confidence interval [CI] 1.0-2.3; p = 0.14 by log-rank). A group of 346 children were vaccinated according to protocol (ATP). Among these children, the hazard ratio was 1.3 (95% CI 0.8-2.1; p = 0.55 by log-rank). When multiple malaria episodes were included in the analyses, the incidence rate ratios were 1.6 (95% CI 1.1-2.3); p = 0.017 for ITT, and 1.4 (95% CI 0.9-2.1); p = 0.16 for ATP. Haemoglobin and parasitaemia in cross-sectional surveys at 3 and 9 mo did not differ by treatment group. Among children vaccinated with FFM ME-TRAP, there was no correlation between immunogenicity and malaria incidence.
No protection was induced against febrile malaria by this vaccine regimen. Future field studies will require vaccinations with stronger immunogenicity in children living in malarious areas.

Download full-text


Available from: Oscar Kai, Aug 27, 2015
  • Source
    • "In the current paper, to avoid this potential limitation, both PCR protocols were performed with 2 μL of template, which corresponded to approximately 6 μL of the whole blood collected from the patient. Because the use of templates isolated from substantially higher volumes of blood might encounter difficulties due to the high quantities of human DNA, blood filtration methods for the removal of leukocytes have been proposed to increase the PCR sensitivity during malaria vaccine clinical trials (Andrews et al. 2005, Bejon et al. 2006). After performing a multistep protocol, during which 5 mL of blood was filtered to remove the leukocytes, Andrews et al. (2005) established a PCR cut-off point of 20 parasites/mL to follow the vaccinated volunteers in the Phase II trials. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The polymerase chain reaction (PCR)-based methods for the diagnosis of malaria infection are expected to accurately identify submicroscopic parasite carriers. Although a significant number of PCR protocols have been described, few studies have addressed the performance of PCR amplification in cases of field samples with submicroscopic malaria infection. Here, the reproducibility of two well-established PCR protocols (nested-PCR and real-time PCR for the Plasmodium 18 small subunit rRNA gene) were evaluated in a panel of 34 blood field samples from individuals that are potential reservoirs of malaria infection, but were negative for malaria by optical microscopy. Regardless of the PCR protocol, a large variation between the PCR replicates was observed, leading to alternating positive and negative results in 38% (13 out of 34) of the samples. These findings were quite different from those obtained from the microscopy-positive patients or the unexposed individuals; the diagnosis of these individuals could be confirmed based on the high reproducibility and specificity of the PCR-based protocols. The limitation of PCR amplification was restricted to the field samples with very low levels of parasitaemia because titrations of the DNA templates were able to detect < 3 parasites/µL in the blood. In conclusion, conventional PCR protocols require careful interpretation in cases of submicroscopic malaria infection, as inconsistent and false-negative results can occur.
    Memórias do Instituto Oswaldo Cruz 02/2014; 109(1):21-8. DOI:10.1590/0074-0276140102 · 1.57 Impact Factor
  • Source
    • "and have been followed up as above, for clinical episodes of malaria [20] [24]. In addition, trained field workers were available in the village to conduct passive surveillance. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Antibodies to selected Plasmodium falciparum merozoite antigens are often reported to be associated with protection from malaria in one epidemiological cohort, but not in another. Here, we sought to understand this paradox by exploring the hypothesis that a threshold concentration of antibodies is necessary for protection. We analyzed data from two independent cohorts along the Kenyan coast, one in which antibodies to AMA1, MSP-2 and MSP-3 were associated with protection from malaria (Chonyi) and another in which this association was not observed (Junju). We used a malaria reference reagent to standardize antibody measurements across both cohorts, and applied statistical methods to derive the threshold concentration of antibodies against each antigen that best correlated with a reduced risk of malaria (the protective threshold), in the Chonyi cohort. We then tested whether antibodies in Junju reached the protective threshold concentrations observed in the Chonyi cohort. Except for children under 3 years, the age-matched proportions of children achieving protective threshold concentrations of antibodies against AMA1 and MSP-2 were significantly lower in Junju compared to Chonyi (Fishers exact test, P<0.01). For MSP-3, this difference was significant only among 4-5 year olds. We conclude that although antibodies are commonly detected in malaria endemic populations, they may be present in concentrations that are insufficient for protection. Our results have implications for the analysis and interpretation of similar data from immuno-epidemiological studies.
    Vaccine 06/2013; 31(37). DOI:10.1016/j.vaccine.2013.06.042 · 3.49 Impact Factor
  • Source
    • "Collectively, these studies suggest that other non-CSP antigens play an important role in pre-erythrocytic stage protective immunity. Failure to protect against field challenge has also been noted with candidate vector vaccines based on another pre-erythrocytic stage antigen, SSP2/TRAP (fused to multiple T cell epitopes derived from other pre-erythrocytic stage antigens) even though the vaccines were immunogenic (Moorthy et al., 2004;Bejon et al., 2006) and conferred a delay in onset of blood-stage parasitemia following sporozoite challenge in malaria-naïve adults (McConkey et al., 2003). In the case of the asexual blood-stage, recent clinical trials with the two leading candidate antigens, apical membrane antigen 1 (AMA1) and merozoite surface protein 1 (MSP1) have proved disappointing (Malkin et al., 2007;Ogutu et al., 2009;Sagara et al., 2009;Spring et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Plasmodium parasite, the causative agent of malaria, is an excellent model for immunomic-based approaches to vaccine development. The Plasmodium parasite has a complex life cycle with multiple stages and stage-specific expression of ∼5300 putative proteins. No malaria vaccine has yet been licensed. Many believe that an effective vaccine will need to target several antigens and multiple stages, and will require the generation of both antibody and cellular immune responses. Vaccine efforts to date have been stage-specific and based on only a very limited number of proteins representing <0.5% of the genome. The recent availability of comprehensive genomic, proteomic and transcriptomic datasets from human and selected non-human primate and rodent malarias provide a foundation to exploit for vaccine development. This information can be mined to identify promising vaccine candidate antigens, by proteome-wide screening of antibody and T cell reactivity using specimens from individuals exposed to malaria and technology platforms such as protein arrays, high throughput protein production and epitope prediction algorithms. Such antigens could be incorporated into a rational vaccine development process that targets specific stages of the Plasmodium parasite life cycle with immune responses implicated in parasite elimination and control. Immunomic approaches which enable the selection of the best possible targets by prioritising antigens according to clinically relevant criteria may overcome the problem of poorly immunogenic, poorly protective vaccines that has plagued malaria vaccine developers for the past 25 years. Herein, current progress and perspectives regarding Plasmodium immunomics are reviewed.
    International journal for parasitology 01/2011; 41(1):3-20. DOI:10.1016/j.ijpara.2010.08.002 · 3.40 Impact Factor
Show more